Nomura Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Nomura Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-101,950	Closed	-$2.44M	–	1868
2025 Q3	$2.18M	Buy	+101,950	New	+$2.41M	﹤0.01%	1108
2023 Q2	–	Sell	-365,662	Closed	-$6.88M	–	1331
2023 Q1	$6.88M	Sell	365,662 -562,204	-61%	-$10.7M	0.02%	464
2022 Q4	$14.8M	Buy	927,866 +861,409	+1,296%	+$13.5M	0.06%	234
2022 Q3	$1.09M	Sell	66,457 -9,355	-12%	-$152K	﹤0.01%	932
2022 Q2	$1.09M	Buy	+75,812	New	+$1.41M	﹤0.01%	935
2014 Q3	–	Sell	-16,291	Closed	-$366K	–	2734
2014 Q2	$366K	Buy	+16,291	New	+$340K	﹤0.01%	1989
2013 Q4	–	Sell	-85,094	Closed	-$2.34M	–	1967
2013 Q3	$2.34M	Buy	+85,094	New	+$1.78M	0.01%	779

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nomura Holdings's ACAD Position: Q4 2025 in Review

Nomura Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 101,950 shares — an estimated $2.44M sold.

Nomura Holdings first reported a position in ACAD in Q3 2013 and held it in 7 quarters. The position peaked at $14.8M in Q4 2022. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Nomura Holdings reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Nomura Holdings sold 101,950 Acadia Pharmaceuticals shares in Q4 2025, an estimated $2.44M.
Nomura Holdings first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Nomura Holdings's Acadia Pharmaceuticals position peaked at $14.8M in Q4 2022.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Nomura Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.